Flamingo Therapeutics, Progyny name chief medical officers

Andrew Denker, MD, PhD, has been named chief medical officer of Flamingo Therapeutics, an oncology-focused biotechnology company.

Advertisement

Dr. Denker is a physician scientist with more than two decades of clinical development experience in the biotechnology and pharmaceutical industry, according to an April 4 news release from the company. He most recently served as vice president of early development at ElevateBio Technologies.

As chief medical officer, Dr. Denker will oversee the expansion of Flamingo’s clinical portfolio out of the company’s U.S. headquarters in Philadelphia.

Meanwhile, Janet Choi, MD, has been named chief medical officer of fertility benefits management company Progyny.

Dr. Choi has served on the company’s medical advisory board for three years, according to an April 4 news release from the company. She officially joins Progyny with more than 20 years of experience as a specialist in reproductive endocrinology, obstetrics and gynecology.

Dr. Choi most recently spent seven years as the medical director of CCRM New York and previously taught as an assistant clinical professor in obstetrics and gynecology at Columbia University Medical Center in New York City.

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 18–20 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Chief Medical Officers

Advertisement

Comments are closed.